Detalhe da pesquisa
1.
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Breast Cancer Res
; 24(1): 71, 2022 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307826
2.
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Oncologist
; 20(9): 1001-10, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26245675
3.
Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.
NPJ Breast Cancer
; 7(1): 12, 2021 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33579951
4.
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
J Clin Oncol
; 32(10): 1050-7, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24590635
5.
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
J Clin Oncol
; 30(16): 1989-95, 2012 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22493419